Precision Medicine in Castration-Resistant Prostate Cancer
10.22465/kjuo.2018.16.3.97
- Author:
Won Tae KIM
1
;
Seok Joong YUN
;
Wun Jae KIM
Author Information
1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. sjyun@chungbuk.ac.kr, wjkim@chungbuk.ac.kr
- Publication Type:Review
- Keywords:
Prostatic neoplasms;
Precision medicine;
Prostatic neoplasms;
Castration-resistant
- MeSH:
Drug Therapy;
Humans;
Precision Medicine;
Prostate;
Prostatic Neoplasms
- From:Korean Journal of Urological Oncology
2018;16(3):97-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Prostate cancer is usually managed by androgen deprivation therapy after failure of primary treatment. However, such therapies are only temporarily effective in prostate cancer patients, and the most patients experience the progression to castration-resistant prostate cancer (CRPC). Docetaxel chemotherapy is conventional effective treatment for CRPC but has many adverse effects. In CRPC patients, treatment decisions were not typically base on the recognitions of inter-individual differences. Therefore, there are growing interests for precision medicine in CRPC. In this review, we summarized the precision medicine such as candidate target genes and potential therapies in CRPC.
